Practical Cheat Sheet for Indian Clinicians (2026) 1. What Just Changed Semaglutide patent expired (21 March 2026). Multiple Indian generics launched within days (Sun, Zydus, Dr. Reddy’s, Natco, Glenmark, Alkem, Lupin). Monthly cost dropped from ~₹8,800–₹16,000 to ~₹3,000–₹4,000; some weekly doses ~₹450. Weight-loss market (~₹1,400 crore) expected to double in 12 months. Expect: high patient demand, self-prescription attempts, social-media driven expectations. 2. Mechanism – 10‑Second Recall Semaglutide = GLP‑1 receptor agonist. Pancreas (β‑cells): Glucose‑dependent ↑ insulin → HbA1c ↓ with low hypoglycaemia risk (if not combined with SU/insulin). Glucagon: ↓ glucagon → ↓ hepatic glucose output. CNS & Gut: Delays gastric emptying, ↑ satiety, ↓ appetite → caloric deficit and weight loss. Key original brands: Ozempic (SC weekly, T2DM), Wegovy (SC weekly, obesity), Rybelsus (oral, daily, T2DM). Indian generics (examples, March 2026): Noveltreat, Sematrinity, Semaglyn, Mashema + others from Dr. Reddy’s, Natco, Glenmark, Alkem, Lupin. 3. Who SHOULD Get Semaglutide? A. Type 2 Diabetes (T2DM) Consider if ALL are true: Inadequate control: HbA1c above individualised target despite metformin ± one other agent. Weight benefit desired: BMI ≥25 kg/m² (Indian cut‑off) OR central obesity. AND at least one of: Established ASCVD (prior MI, stroke/TIA, PAD, documented CAD). High hypoglycaemia risk where sulphonylureas/insulin are problematic. Need to avoid weight gain from other agents (e.g., SU, insulin, TZDs). Evidence: SUSTAIN‑6 – ~26% relative risk reduction in MACE (CV death, non‑fatal MI, non‑fatal stroke). B. Chronic Weight Management (Obesity) Use ONLY as part of a structured obesity management plan (diet, activity, behaviour). Eligible if: BMI ≥30 kg/m², OR BMI ≥27.5 kg/m² (Asian/Indian cut‑off) with ≥1 comorbidity: Hypertension Dyslipidaemia OSA NAFLD/MASLD Type 2 diabetes or prediabetes AND Documented failure of 3–6 months of structured lifestyle intervention. 4. Who Should NOT Get It? (Absolute Contraindications) Personal or family history of medullary thyroid carcinoma (MTC). MEN2 (Multiple Endocrine Neoplasia type 2). Pregnancy or planning pregnancy; avoid in breastfeeding. Severe renal impairment: eGFR <15 mL/min/1.73 m² (use great caution if eGFR <30). Also generally avoid or use extreme caution in: History of pancreatitis (especially recurrent or idiopathic). Severe GI disease with gastroparesis. 5. Front‑Desk & OPD Script (Practical Talking Points) Use simple, consistent language with patients: “This is a prescription‑only medicine.” No OTC, no sharing pens. “It is not a cosmetic weight‑loss injection.” Reserved for diabetes/obesity with medical indications. “Results are slow and steady.” Expect meaningful weight change over 3–6 months, not weeks. “Lifestyle is mandatory.” Diet, activity, sleep, and alcohol control remain central. “We will stop or adjust if you get side effects.” Nausea, vomiting, abdominal pain, or signs of pancreatitis need review. 6. Immediate Action Points for Your Practice Create a one‑page internal protocol: Eligibility criteria (T2DM + obesity as above). Contraindications checklist. Basic titration plan per brand you stock. Train staff to: Screen calls: pregnancy, thyroid cancer history, MEN2, severe kidney disease. Book longer first consults for semaglutide discussions. Standardise documentation: Baseline: weight, BMI, waist, BP, HbA1c, lipids, eGFR, LFTs. Review at 3 months: weight, BMI, HbA1c, adverse effects. Prepare a patient handout (1–2 pages) summarising: Why they qualify. How to use the injection. Common side effects and red‑flag symptoms. This framework should let you respond calmly to the current surge in demand, prescribe to the right patients, and avoid the highest‑risk misuse as low‑cost generics flood the Indian market. Practical Summary: Indian Generic Semaglutide for Your Clinic 1. Dosing Protocols A. Type 2 Diabetes – SC Weekly (Ozempic-equivalent generics) Weeks 1–4: 0.25 mg once weekly Goal: assess tolerability, minimise GI side effects. Weeks 5–8: 0.5 mg once weekly Goal: reach efficacy threshold for HbA1c and weight. Week 9 onwards: 1 mg once weekly (usual max for diabetes in India) Goal: optimal glycaemic control; individualise based on response and side effects. Device caution (Noveltreat, Sematrinity, etc.): Always confirm pen strength and unit markings before counselling. Some pens are labelled in mg, others in “dose units”. Do a live demo with a demo pen or trainer device. B. Obesity / Weight Management – SC Weekly (Wegovy-equivalent logic) Standard obesity titration (where 2.4 mg formulation is available): 0.25 mg weekly → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly (each step usually 4 weeks) In India currently: most generics are approved for diabetes doses (up to 1 mg). Check each brand’s DCGI-approved indication and max dose before using for pure obesity. For non-diabetic obesity, document BMI and comorbidities clearly in notes and prescription. C. Oral Semaglutide (Rybelsus-equivalent) Dosing: 3 mg once daily × 30 days then 7 mg once daily then 14 mg once daily (if needed and tolerated) Administration rules (critical for efficacy): Take on completely empty stomach with up to 120 mL plain water only. Wait at least 30 minutes before any food, drink (including tea/coffee), or other oral medicines. If a dose is missed, skip and take next dose at the usual time (no double dosing). 2. Side Effects – What to Counsel Every Patient Common (usually manageable – do not stop drug immediately): Nausea (most frequent, especially in first 4 weeks and after dose increases) Advise: small, frequent meals; avoid oily, spicy, very large meals; stop eating when comfortably full. Vomiting Diarrhoea or constipation Decreased appetite / early satiety Counselling tip: Warn patients before starting that mild–moderate GI symptoms are expected and usually settle in 2–4 weeks. Encourage them not to stop on their own but to call the clinic if symptoms are troublesome. Serious – stop semaglutide and review urgently: Acute pancreatitis Symptoms: severe, persistent upper abdominal pain (often radiating to back), vomiting. Action: stop drug, check serum amylase/lipase, refer/admit as needed. Thyroid nodule / possible medullary thyroid carcinoma Symptoms: neck swelling, new-onset hoarseness, difficulty swallowing/breathing. Action: stop drug, urgent endocrinology/ENT referral. Severe hypoglycaemia (mainly when combined with sulfonylurea or insulin) Action: consider reducing sulfonylurea/insulin doses when starting/titrating semaglutide; educate on hypo recognition and treatment. Acute kidney injury Often secondary to dehydration from vomiting/diarrhoea in patients with pre-existing CKD. Action: monitor creatinine/eGFR, ensure adequate hydration, consider temporary drug hold. 3. India-Specific Practical Issues Storage: Unused pens: 2–8°C (refrigerated), do not freeze. After first use: can be kept at room temperature (follow brand-specific label, typically up to 28 days). Protect from direct sunlight and heat; maintain cold chain during transport. Device training: With multiple pen designs in the market, device errors are common. Consider a nurse-led training session for first-time users: How to attach needle, prime (if required), select dose, inject, and dispose of sharps. Reinforce weekly same-day, same-time dosing. Switching brands: Avoid switching between different generic brands or between generic and originator mid-treatment, unless supply or cost issues demand it. If switching is unavoidable, document clearly and re-check dose equivalence and pen strength. 4. Generic vs Branded – Key Talking Points for Doctors Bioequivalence vs clinical equivalence Indian generics have been approved as bioequivalent to reference semaglutide at approved doses. Semaglutide is a large peptide, not a simple small-molecule; long-term, head-to-head clinical data for Indian generics vs Ozempic/Wegovy is still limited. Current expert consensus: approved Indian generics are acceptable alternatives when used under medical supervision. Market dynamics and pricing With 40+ brands entering, expect intense price competition in the short term. Over 12–18 months, market will likely consolidate around brands with: reliable cold-chain and supply, strong post-marketing safety data, consistent device quality. Prescription status Semaglutide is a Schedule H drug in India. Prescription is mandatory; OTC sale is not legal. Warn patients against unregulated online sellers and “weight-loss injections” without proper labelling or prescription. 5. FAQ for Patients (SEO-Friendly Q&A) Q1: Is generic semaglutide as effective as Ozempic? A: Approved Indian generics have passed regulatory bioequivalence requirements, suggesting comparable efficacy at labelled doses. However, long-term real-world data in Indian patients is still evolving. When prescribed and monitored by a doctor, these generics are considered clinically acceptable alternatives. Q2: Can I take semaglutide just for weight loss if I’m not diabetic? A: Only if you meet medical criteria and your doctor confirms the indication: BMI ≥30 kg/m², or BMI ≥27.5 kg/m² with at least one obesity-related comorbidity (e.g., MASLD, hypertension, dyslipidaemia, OSA). It is not a cosmetic slimming injection and should never be self-prescribed. Q3: What happens if I stop taking semaglutide? A: Weight: Most people regain some or all of the lost weight over time unless they have made sustained lifestyle changes (diet, activity, behaviour). Diabetes control: HbA1c and blood sugars usually rise again if semaglutide was a key part of your treatment. Stopping should be done under medical guidance, with a plan for alternative therapy and lifestyle support. Q4: Can I take semaglutide if I have fatty liver (MASLD)? A: Yes, many patients with obesity and type 2 diabetes also have MASLD, and this is actually one of the comorbidities that can support eligibility for weight management treatment. Emerging data suggests semaglutide may improve liver fat and inflammation, but this is still an evolving indication. You should be monitored for liver health as part of your overall metabolic care. Q5: Is semaglutide safe for Indian patients? A: Large global trials included Asian participants, and Indian approval is based on demonstrated safety and efficacy. However, South Asians develop metabolic disease at lower BMI and may have different risk profiles. Doctors therefore: Use lower BMI thresholds for risk, Individualise dosing and titration, Monitor GI tolerance, kidney function, and glycaemic response closely. Q6: Which Indian brand of semaglutide is best? A: There is no universally “best” brand. Rational selection should consider: Regulatory status and quality track record of the manufacturer, Cold-chain reliability and consistent availability, Pen design and ease of use for your specific patient, Pharmacy/distributor reliability, Cost, but not cost alone. Doctors should avoid frequent brand switching and should document the exact brand, strength, and device type on every prescription. 6. How DocTrust Helps You Run a Semaglutide-Ready Clinic The rapid expansion of generic semaglutide in India will significantly increase OPD queries and follow-ups over the next 6–12 months. Clinics that succeed will combine sound clinical protocols with a robust digital workflow. DocTrust can support you by: Structured EMR templates for semaglutide starts and follow-ups: Baseline BMI, waist, HbA1c, lipids, LFT, RFT, comorbidities. Automated capture of dose, brand, and device. Digital prescriptions with: Auto-flagging of drug interactions (e.g., sulfonylureas, insulin, renal risk). Clear, standardised patient instructions for injection technique and oral dosing. Appointment management: Dedicated “semaglutide review” slots at 4, 8, and 12 weeks. Easy tracking of titration steps and side-effect checks. WhatsApp reminders and follow-up nudges: Weekly reminders for injection day. 3‑month follow-up prompts to improve adherence and outcome tracking. When 20–30 patients in a single OPD session are asking about Ozempic generics, you need more than memory and paper notes. You need a digital backbone that standardises care, reduces errors, and frees your time for clinical decision-making. Ready to make your clinic semaglutide-ready? Book a demo at www.doctrust.in and see how DocTrust can integrate directly into your current OPD workflow.